{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:37:28Z","timestamp":1776393448209,"version":"3.51.2"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ad.2023.09.006","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T02:03:00Z","timestamp":1694656980000},"page":"356-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anticolin\u00e9rgicos t\u00f3picos en el manejo de la hiperhidrosis focal en adultos y ni\u00f1os. Una revisi\u00f3n narrativa"],"prefix":"10.1016","volume":"115","author":[{"given":"D.","family":"Morgado-Carrasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.09.006_bib0285","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2018.12.071","article-title":"The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/pde.13723","article-title":"Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials","volume":"36","author":"Hebert","year":"2019","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0295","first-page":"5","article-title":"Primary focal hyperhidrosis: scope of the problem","volume":"79","author":"Glaser","year":"2007","journal-title":"Cutis."},{"key":"10.1016\/j.ad.2023.09.006_bib0300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/iwj.13004","article-title":"Relationship between depression scores and degree of skin perspiration: A novel cross-sectional study","volume":"16","author":"L\u00f3pez-L\u00f3pez","year":"2019","journal-title":"Int Wound J."},{"key":"10.1016\/j.ad.2023.09.006_bib0305","first-page":"adv00044","article-title":"Association of Primary Hyperhidrosis with Depression and Anxiety: A Systematic Review","volume":"100","author":"Kristensen","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2023.09.006_bib0310","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40257-022-00743-7","article-title":"The Impact of Hyperhidrosis on Quality of Life: A Review of the Literature","volume":"24","author":"Parashar","year":"2023","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0315","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2340\/00015555-2755","article-title":"Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms. Consequences and Treatment with Botulinum Toxin","volume":"98","author":"Mirkovic","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2023.09.006_bib0320","first-page":"1","article-title":"Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis","volume":"24","author":"Nwannunu","year":"2019","journal-title":"Skin Ther Lett."},{"key":"10.1016\/j.ad.2023.09.006_bib0325","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ad.2014.11.012","article-title":"Systemic treatment of hyperhidrosis","volume":"106","author":"del Boz","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2023.09.006_bib0330","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/jdv.14081","article-title":"Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review","volume":"31","author":"Cruddas","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2023.09.006_bib0335","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/14656566.2022.2083499","article-title":"The pharmacological treatment and management of hyperhidrosis","volume":"23","author":"Campanati","year":"2022","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.ad.2023.09.006_bib0340","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/toxins15020147","article-title":"Efficacy and Safety of Botulinum Toxin B in Focal Hyperhidrosis: A Narrative Review","volume":"15","author":"Campanati","year":"2023","journal-title":"Toxins."},{"key":"10.1016\/j.ad.2023.09.006_bib0345","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10286-019-00640-w","article-title":"Radiofrequency in the treatment of primary hyperhidrosis: systematic review and meta-analysis","volume":"30","author":"Hasimoto","year":"2020","journal-title":"Clin Auton Res."},{"key":"10.1016\/j.ad.2023.09.006_bib0350","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/jocd.14378","article-title":"Treatment of Axillary hyperhidrosis","volume":"21","author":"Arora","year":"2022","journal-title":"J Cosmet Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0355","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/ijd.15937","article-title":"The treatment of palmar hyperhidrosis - a systematic review","volume":"61","author":"Chudry","year":"2022","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0360","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/pde.12142","article-title":"Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old","volume":"31","author":"Wolosker","year":"2014","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0365","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2010.03.013","article-title":"Clinical differentiation of primary from secondary hyperhidrosis","volume":"64","author":"Walling","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0370","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaad.2018.11.066","article-title":"The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol."},{"issue":"Suppl 1","key":"10.1016\/j.ad.2023.09.006_bib0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2133.2011.10786.x","article-title":"Clinical studies of sweat rate reduction by an over-the-counter soft-solid antiperspirant and comparison with a prescription antiperspirant product in male panelists","volume":"166","author":"Swaile","year":"2012","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0380","first-page":"477","article-title":"An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis","volume":"8","author":"Flanagan","year":"2009","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0385","doi-asserted-by":"crossref","first-page":"e14354","DOI":"10.1111\/dth.14354","article-title":"Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: A randomized controlled trial","volume":"33","author":"Thianboonsong","year":"2020","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2023.09.006_bib0390","first-page":"221","article-title":"Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis","volume":"7","author":"Flanagan","year":"2008","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0395","first-page":"115","article-title":"Hyperhidrosis plantaris - a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminium chloride","volume":"10","author":"Streker","year":"2012","journal-title":"J Dtsch Dermatol Ges."},{"key":"10.1016\/j.ad.2023.09.006_bib0400","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/pde.14551","article-title":"Primary hyperhidrosis in children: A review of therapeutics","volume":"38","author":"Remington","year":"2021","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0405","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jdv.18843","article-title":"Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial","volume":"37","author":"Szeimies","year":"2023","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2023.09.006_bib0410","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjd.19810","article-title":"A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial","volume":"185","author":"Abels","year":"2021","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0415","first-page":"229","article-title":"Safety and efficacy of topical formulations containing 0 5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study","volume":"182","author":"Masur","year":"2020","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0420","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaad.2018.07.002","article-title":"Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials","volume":"80","author":"Glaser","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0425","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40257-018-0395-0","article-title":"Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials","volume":"20","author":"Pariser","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0430","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40257-019-00446-6","article-title":"A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis","volume":"20","author":"Glaser","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/1346-8138.16188","article-title":"Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study","volume":"49","author":"Yokozeki","year":"2022","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0440","first-page":"E61","article-title":"Treatment of Axillary Bromhidrosis with Topical 2% Glycopyrronium Bromide Cream: A Prospective, Non-randomizedm, Open-label Study","volume":"14","author":"Gregoriou","year":"2021","journal-title":"J Clin Aesthetic Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0445","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/13696998.2020.1855879","article-title":"Cost-effectiveness of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis","volume":"24","author":"Bloudek","year":"2021","journal-title":"J Med Econ."},{"key":"10.1016\/j.ad.2023.09.006_bib0450","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/pde.14135","article-title":"Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study","volume":"37","author":"Hebert","year":"2020","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0455","doi-asserted-by":"crossref","first-page":"488","DOI":"10.36849\/JDD.6688","article-title":"Open-Label Cohort Study to Evaluate Efficacy and Safety of Application of Glycopyrronium Cloth, 2.4% for Palmar Hyperhidrosis","volume":"21","author":"Pariser","year":"2022","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0460","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jdv.12518","article-title":"Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study","volume":"29","author":"Hyun","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2023.09.006_bib0465","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1365-2133.2008.08476.x","article-title":"Topical glycopyrrolate for patients with facial hyperhidrosis","volume":"158","author":"Kim","year":"2008","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0470","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/DSS.0000000000003490","article-title":"Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature","volume":"48","author":"Nofal","year":"2022","journal-title":"Dermatol Surg."},{"key":"10.1016\/j.ad.2023.09.006_bib0475","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.2340\/00015555-2731","article-title":"Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study","volume":"97","author":"Artzi","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2023.09.006_bib0480","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/jocd.15715","article-title":"Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial","volume":"22","author":"Saki","year":"2023","journal-title":"J Cosmet Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0485","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2023.03.025","article-title":"A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study in Japan","volume":"89","author":"Fujimoto","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0490","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/pde.13404","article-title":"Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults","volume":"35","author":"Nguyen","year":"2018","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0495","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.15668","article-title":"A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis","volume":"48","author":"Yokozeki","year":"2021","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0500","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/1346-8138.15927","article-title":"A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis","volume":"48","author":"Fujimoto","year":"2021","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/jdv.14651","article-title":"A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis","volume":"32","author":"Nasir","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2023.09.006_bib0510","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00403-023-02587-5","article-title":"Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials","volume":"315","author":"El-Samahy","year":"2023","journal-title":"Arch Dermatol Res."},{"key":"10.1016\/j.ad.2023.09.006_bib0515","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/ijd.14872","article-title":"Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases","volume":"59","author":"Wolosker","year":"2020","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0520","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/jdv.14734","article-title":"Survival study of treatment adherence by patients given oral oxibutynin for hyperhidrosis","volume":"32","author":"Mill\u00e1n-Cayetano","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2023.09.006_bib0525","doi-asserted-by":"crossref","first-page":"e14658","DOI":"10.1111\/dth.14658","article-title":"Craniofacial hyperhidrosis: Clinical characteristics and response to treatment in a cohort of 97 patients treated with oral oxybutynin","volume":"34","author":"Garcia-Souto","year":"2021","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2023.09.006_bib0530","first-page":"e14197","article-title":"Tolerance of oral oxybutynin in the treatment of hyperhidrosis","volume":"33","author":"Del Boz Gonzalez","year":"2020","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2023.09.006_bib0535","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/pde.12385","article-title":"Long-Term Efficacy of Oxybutynin for Palmar and Plantar Hyperhidrosis in Children Younger than 14 Years","volume":"32","author":"Wolosker","year":"2015","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0540","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40257-015-0136-6","article-title":"Treatment of Primary Craniofacial Hyperhidrosis: A Systematic Review","volume":"16","author":"Nicholas","year":"2015","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2023.09.006_bib0545","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neubiorev.2021.04.031","article-title":"Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis","volume":"127","author":"Zheng","year":"2021","journal-title":"Neurosci Biobehav Rev."},{"key":"10.1016\/j.ad.2023.09.006_bib0550","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023007330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023007330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T19:42:38Z","timestamp":1720554158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731023007330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0001731023007330"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.09.006","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticolin\u00e9rgicos t\u00f3picos en el manejo de la hiperhidrosis focal en adultos y ni\u00f1os. Una revisi\u00f3n narrativa","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}